Watson Pharmaceuticals, Incorporated is a leading, integrated global pharmaceutical company. With global headquarters in Parsippany, New Jersey. USA, the company is engaged in the development, manufacture, marketing and distribution of generic pharmaceuticals in a number of therapeutic categories and specialized branded pharmaceutical products that are focused on Urology, Women’s Health and Pain Management. The company is developing biosimilar products in Women’s Health, Oncology and Diabetics. Watson also distributes generic and branded pharmaceuticals through their Anda, Inc. distribution business.

 

On October 31, 2012 Watson completed the acquisition of the privately held Actavis, creating the world’s third largest generics company with 2012 expected revenue in excess of $8.0 billion.

 

The acquisition combines two growing, successful and profitable companies into a strong global generics player operating in more than 60 countries and serving more than 5 billion potential consumers. The company holds a leading position in key established commercial markets including the U.S., Canada, Western Europe, Central and Eastern Europe, Russia, Southeast Asia and Australia.

 

Watson has a core leadership position in modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables. The combined Company has an industry leading global product portfolio of over 750 molecules offered in more than 1,700 different combinations and dosage forms.

 

In the U.S., The combined company’s U.S. pipeline includes approximately 180 unique ANDAs pending at the FDA, including 47 First-to-Files. Outside of the U.S., the current pipeline includes more than 2,000 marketing authorizations pending approval. In April 2012 Watson announced its intention to acquire the global generic pharmaceutical company Actavis. The transaction is expected to close in the fourth quarter of 2012. As a result of the proposed acquisition, the combined company will become the third largest generic pharmaceutical company in the world.

 

The combined company will have commercial operations in more than 60 countries. Actavis' exceptional global strength, including leading market positions in key established commercial markets in Europe and in emerging markets in Central and Eastern Europe and Russia, complements Watson's position in established markets in Western Europe, the US, Southeast Asia and Australia. The combined company will hold a top 3 position in 11 markets and a top 5 market position in 17 markets.

 

Watson’s reported sales in 2011 were $4.57 billion, and it ended the year as the 4th largest generic pharmaceutical company in the world based on number of prescriptions dispensed.

 

Watson's Global Generics division markets more than 190 pharmaceutical product families in the United States, its largest generics market, and has operations in more than 20 countries. Watson's Global Brands division markets more than 36 pharmaceutical products, predominately in the United States, as well as in Canada and Latin America. In addition, Watson's Distribution division, Anda, Inc., markets more than 8,500 items from more than 200 manufacturers, making it the 4th largest generic pharmaceutical distribution company in the United States.